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Abstract
Background: Antigen-specific CD8+ cytotoxic T lymphocytes represent potent effector cells of the adaptive
immune response against viruses as well as tumours. Therefore assays capable at exploring the generation and
function of cytotoxic T lymphocytes represent an important objective for both clinical and experimental settings.
Methods: Here we show a simple and reproducible assay for the evaluation of antigen-specific CD8+ cytotoxic T
lymphocytes based on a LysiSpot technique for the simultaneous determination of antigen-specific IFN-g
production and assessment of tumor cytolysis. The assay was developed within an experimental model of
colorectal carcinoma, induced by the colorectal tumor cell line DHD-K12 that induces tumors in BDIX rats and, in
turn, elicits a tumor- specific immune response.
Results: Using DHD-K12 cells transfected to express Escherichia coli b-galactosidase as target cells, and by the fine
setting of spot colours detection, we have developed an in vitro assay that allows the recognition of cytotoxic T
lymphocytes induced in BDIX rats as well as the assessment of anti-tumour cytotoxicity. The method highlighted
that in the present experimental model the tumour antigen-specific immune response was bound to killing target
cells in the proportion of 55%, while 45% of activated cells were not cytotoxic but released IFN-g. Moreover in this
model by an ELISPOT assay we demonstrated the specific recognition of a nonapeptide epitope called CSH-275
constitutionally express in DHD-K12 cells.
Conclusions: The assay proved to be highly sensitive and specific, detecting even low frequencies of cytotoxic/
activated cells and providing the evaluation of cytokine-expressing T cells as well as the extent of cytotoxicity
against the target cells as independent functions. This assay may represent an important tool to be adopted in
experimental settings including the development of vaccines or immune therapeutic strategies
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Background
A major effort in the tumour immunology research area
is directed to the identification of tumor antigens for
the development of specific anti-tumour immune thera-
pies. Several putative anti-cancer vaccines have been
studied in animal models through immunization with
intact tumour cells, cancer-related peptides, Ag-loaded
dendritic cells (DCs), different viral delivery systems as
well as vaccines combined with adoptive T-cell therapy
[1-3]. The enhanced anti-cancer activity, elicited by
these different approaches of immunization, is mediated
either by the generation of specific CD8+ T cells or by
an enhancement of their functional activity [4]. A num-
ber of clinical trials have indicated that anti-tumor vac-
cination and active immunotherapy with tumor-specific
peptide vaccines represent a promising therapeutic tool
against cancer. Ideally, an effective vaccine should
induce specific cytolytic immune cells against molecular
targets expressed only on tumor cells. On this basis, a
correct and accurate detection and quantification of
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antigen-specific CTLs represent an essential requirement
for monitoring vaccine efficacy and may provide a criti-
cal biomarker for vaccine assessment in preclinical and
clinical studies on both vaccine and drug development.
While the antigen-specific T cells recognition occurs
at very low frequencies in the blood, it requires the
assays extremely sensitive as flow cytometry technique
[5], tetramer/pentamer binding techniques [6], CD107
mobilization assay [7] or Fluorospot assays for cytokine
secretion [8].
The ELISpot assay, which can detect antigen-activated
T cells frequencies as low as 1/1,000,000, offers a reli-
able evaluation of the frequencies of these cells among
peripheral blood mononuclear cells (PBMC) [9]. In fact,
ELISpot assay for IFN-g and granzyme B [10], have
gained increasing popularity to measure CTL activity
and are routinely used. Nevertheless, antigen-activated T
cells may not always secrete the all set of their potential
cytokine production [11] and conversely, cytotoxicity
does not always correlate with IFN-g secretion in bulk
PBMC populations [12-14]. For this reason, few years
ago has been proposed a LysiSpot assay, which is cap-
able to detect cytotoxic T cells, and to provide an eva-
luation of the target cell lysis by measuring the release
of a foreign marker protein [15]. In the original paper,
the target tumour cells were transduced by an herpes
simplex virus (HSV) amplicon vector to express Escheri-
chia coli b-galactosidase (b-gal) as the marker protein.
In this study we used an experimental model of a col-
orectal carcinoma induced by the tumour cell line
DHD-K12 in syngeneic immunocompetent BDIX rats
[16]. This model, closely mimics the characteristics of
human cancer (colorectal carcinoma) counterpart, being
very useful to assess specific tumour immunotherapy
strategies. In fact, DHD-K12 cells constitutionally
express a nonapeptide epitope called CSH-275. The
CSH-275 is present in tissue specimens from colorectal
neoplasia but not in the normal mucosa of BDIX rats.
The inoculation of CSH-275 peptide in tumour-har-
bouring rats induces a significant increase in CTLs
activity against autologous DHD-K12 cells [17]. In addi-
tion, this nonapeptide is a major epitope identified on
the Tumour Liberated Proteins (TLP) isolated from
human colorectal cancer as well as in human lung and
breast tumours [16-20].
Therefore, in this experimental model we adopted a
modified version of the LysiSpot assay, based on a non
viral transfection method to obtain ß-gal-expressing
tumor target cells, combined with an IFN-g ELISpot in a
dual-colour testing, aiming at developing a method to
analyze tumour specific immune responses.
Moreover in this paper we confirm that the nonapep-
tide epitope CSH-275 is a good marker for colorectal
cancer since ex vivo lymphocytes from BDIX rats,
primed with DHD-K12 are able to recognize this speci-
fic antigen.
Methods
Rats and tumor cells
Inbred male BDIX rats (Charles River, Calco, Italy), 8
weeks old (average weigh 220-250 g), were held for 7
days, housed in a pathogen-free animal facility and kept
in accordance with European Community guidelines.
The DHD-K12 cell line (kindly obtained from Dr. F.
Martin, Dijon, France), originally established from a 1,2-
dimethylhydrazine-induced colon adenocarcinoma in
syngeneic BDIX rats, was cultured as monolayers in
DMEM supplemented with 10% heat-inactivated FCS, 2
mM L-glutamine, 100 U/ml penicillin and 100 μg/ml
streptomycin at 37°C in a humidified atmosphere of 5%
CO2. All media and supplements were obtained from
Hyclone (Logan, UT). DHD-K12 cells were split 1 day
before tumor challenge, detached with Cell Dissociation
Solution (Sigma, St. Louis, MO), washed and diluted to
the appropriate concentration in sterile PBS solution.
Following a 1-week acclimatation period and after rat
anesthetization by inhalation ofO2 and 1-bromo-2-
chloro-1,1,1-trifluoroethane (Sigma, St Louis, MO, USA)
at 4% concentration through a vaporizer, tumours
DHD-K12 cells (2 × 106 in 0.2 ml/animal) were injected
s.c. in the shaved cervical region of BDIX rats.
Tumor growth (data not shown) was evaluated as pre-
viously described [16].
Rat peripheral blood mononuclear cells
PBMC were obtained by cardiac puncture from 5 intact
healthy rats, or from 5 tumor challenged rats after 30
days from DHD-K12 injection. PBMC were recovered
by centrifugation through a Ficoll-Hypaque gradient
(Lympholyte-H sterile solution Cederlane, Ontario,
Canada), frozen in freezer medium (90% heat inactivated
FBS, Euroclone, and 10% DMSO, Sigma) and kept in
liquid nitrogen until employed as effector cells in the in
vitro assays.
Transfection of target cells
DHD-K12 cells employed as target cells for CTL detec-
tion were transfected by the pCMV-LacZ (kindly pro-
vided by M. Scarpa, University of Padova, Italy),
containing the CMV immediate-early promoter/enhan-
cer and the nuclear targeted b-galactosidase coding
region. The pCMV-LacZ was obtained by using a com-
mercial kit (Qiagen™ Endofree Megaprep, Qiagen S.p.
A., Italy) and following the manufacturer’s supplied pro-
tocol. The identity was confirmed by agarose gel electro-
phoresis of both uncut and restriction digested plasmid.
Contamination with RNA was not observed and the
majority of the plasmid was present as covalently closed
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circles. A lipofectamine transfection standard protocol
was performed in accordance with the manufacturer’s
instructions (Invitrogen s.r.l, Milano, Italy) with some
modifications. Briefly, 2 × 106 cells were plated in 60
mm plates in the presence of 5 ml of DMEM medium
(Euroclone, Pero, Milan, Italy) with 10% FCS (Euro-
clone); after 24 h, the cells reached 90% confluency.
Lipofectamine 2000 (25 μl) was then mixed with 10 μg
of the plasmid pCMV-LacZ in 0.5 ml of DMEM and the
mixture was allowed to stand at room temperature for
20 min. The transfection complex (0.5 ml) Lipofecta-
mine 2000-DNA was added to the plate containing the
cells in a volume of 5 ml of culture medium.
Twenty-four hours after transfection the cells were
stained using the b-Gal Staining kit (Invitrogen) to con-
trol the expression of the LacZ gene product. After
removing growth medium and extensive washing with
PBS, cells were fixed by 20 min of incubation with PBS
containing2% formaldehyde, washed in PBS and then
incubated for 6 h at 37°C with X-gal staining solution (1
mM X-gal, 5 mM potassium ferrocyanide, 2 mM MgCl2
in PBS). Afterwards, cells were checked under a conven-
tional inverted fluorescence microscope to count the
blue-stained, b-gal expressing cells (Figure 1). At least
200 cells were counted in four different fields. Samples
with frequencies of b-gal expressing cells between 60%
and 70% were used as target cells for CTL detection. No
background staining was observed in DHD-K12 cells
transfected with Lipofectamine 2000 without DNA
(negative control).
ELISpot assay for the analysis of IFN-g producing cells
The enumeration of individual cells producing IFN-g,
was performed by a commercially available immunospot
assay kit (PVDF Rat IFN-g ELISpot Kit, Euroclone, Pero,
MI, Italy) following the manufacturer’s instructions with
some modifications. Briefly, polyvinylidene fluoride
microtiter plates (MAIP S45 10, Millipore Sunnyvale,
CA, USA) were coated overnight at 4°C with capture
MoAb anti-IFN-g, dissolved in sterile PBS, 100 μl/well.
Ab-coated plates were then washed and incubated 2 h
at room temperature with complete medium (RPMI
1640, 10% FBS, 1% Penicillin-Sptreptomycin-L-Gluta-
mine; GIBCO-BRL, UK) to prevent non-specific protein
binding.
Cryopreserved PBMC from control or tumour har-
bouring rats were thawed and cultured in triplicate wells
(2 × 105/well) with different concentrations (10-4-2-1
μg/ml) of CSH-275 peptide (gently provided by Cell
Essentials, Boston, MA) in a humidified atmosphere
with 5% CO2 at 37°C. Control wells containing PBMC
with medium alone or with PHA (10 μg/ml, Sigma,
Saint Louis, MO, USA) were also tested.
After 20 h of incubation, cells were lysed with ice-cold
distilled water and removed by rinsing (four times) with
PBS/0.05% Tween® 20 (Sigma, St Louis, MO, USA).
After 90 min incubation with abiotynilated anti-IFN-g
detection MoAb, diluted in PBS with 1% bovine serum
albumin (BSA, fraction V, Sigma, St Louis, MO, USA),
Streptavidin alkaline phosphatase conjugate (diluted in
sterile PBS with 1% BSA) was added to the wells for 45
min at 37°C in the dark. The plates were then washed
and refilled with a ready-to-use BCIP/NBT solution.
Blue spots were let to develop for up to 30 min at r.t. in
the dark. Plates were then washed with distilled water to
stop the reaction and allowed to dry overnight. Spots
were counted by an Automated ImmunoSpot Image
Analyzer Software (AELVIS Tecnologies, TEMA-
Ricerca, Italy). The stimulation index (S.I.) was
expressed by the ratio between the number of spots per
2 × 105 PBMC plated with antigen and those detected
in control wells [21].
The cytotoxic assay
The specific cytotoxic activity of PBMC from DHD-
K12-inoculated rats (Immune, I) or control (Non
Immune NI) was tested by using a Promega CytoTox
96 kit (Promega, Corporation Madison, WI). This col-
orimetric assay quantitatively measures the release of
lactate dehydrogenase (LDH), a stable cytosolic
enzyme. Briefly, target cells were incubated in 96-well
Figure 1 DHD-K12 cells expressing b-gal. DHD-K12 cells were
transiently transfected with a plasmid vector expressing LacZ gene.
Twenty-four hours after transfection, cells were checked for
expression of b-gal through the development of blue colour. Cells
expressing b-gal (mark with an arrow-head) ranged between 50%
and 60% without significant cell death. The images (20x) was
captured using Spot RT software version 3.0 (Diagnostic Instruments,
inc) using a conventional inverted microscope.
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round bottom plates with effector cells in 10:1, 5:1,
2,5:1 and 1,25:1 effector/target cell ratios for 4 h at 37°
C. All samples were run in quadruplicate. Spontaneous
release of effector or target cells was controlled by
separate incubation of the respective population. At
the end of incubation, the cells were lysed and centri-
fuged. 100 μl aliquot of each well was transferred into
another 96 well plate and 100 μl of freshly “LDH sub-
strate solution” was added to each well. The plates
were incubated, light-protected, at room temperature
for additional 10 min, and the reaction was stopped by
the addition of acetic acid 1 M. The resulting light
absorbance was measured in a microplate reader (Mul-
tiskan EX Labsystem) at 490 nm. The percentage of




Ttot − Tsp × 100
where Eexp is the experimental LDH release of co-cul-
tured effector and target cells, Esp and Tsp express the
spontaneous released LDH of the effector and target cell
alone, respectively, and Ttot is the maximum LDH
amount of target cells.
The LysiSpot assay
The LysiSpot assay was set by a procedure similar to
that of the ELISpot assay, with some modifications. In
brief, polyvinylidene fluoride microtiter plates (MAIP
S45 10, Millipore Sunnyvale, CA, USA) were coated
with capture MoAb against b-gal (from mouse fractio-
nated ascites fluid, clone G4644 Sigma, Saint Louis, Mis-
souri, USA) diluted at 12 μg/ml in PBS with 1% BSA.
DHD-K12 target cells were plated 5 h after transfection
at 1-4 × 104/well with effector cells (PBMC at 2 × 105/
well) in complete RPMI medium and cultured for 16 h
at 37°C in a 5% CO2. Biotinylated anti-b-gal detection
MoAb (clone GAL 13 Sigma) diluted at 2 ug/ml in PBS
with 1% BSA was added in a volume of 100 μl/well.
After 90 min, avidin-horseradish peroxidase was added
to the plates and incubated for 1 h incubation at r.t.
(Pierce Biotechnology, Rockford, IL, USA). Plates were
then washed and incubated with AEC-chromogen solu-
tion (BD Biosciences, Belgium) until red spots were
clearly visible.
Dual-colour LysiSpot assay
Plates were coated with a mixture of capture MoAbs
against b-gal and IFN-g. Effector and target cells were
prepared as in the LysiSpot assay (see above). After 16 h
of incubation, Biotinylated anti-IFN-g detection MoAb
was added to the plates, followed by streptavidin-alka-
line phosphatase conjugate. After washing, a 30 min,
incubation with an unrelated biotinylated MoAb (we
used MoAb anti-IL-4 diluted in RPMI) was performed
to block any free streptavidin binding sites. Afterwards,
the biotinylated b-gal detection MoAb was added to the
plates, followed by avidin-horseradish peroxidase conju-
gate. The plates were then incubated sequentially with
the peroxidase substrate AEC and the phosphatase sub-
strate BCIP/NBT to develop respectively red and blue
spots.
The dual-colour settings programme (AELVIS Tech-
nologies, Software-version 4.2 Reader, TEMA-Ricerca,
Italy) allowed to count the spots separately for three dif-
ferent colours. After setting up the limits the spots were
sorted into three groups: pure red (b-gal) or blue spots
(IFN-g) and violet spots (concomitant IFN-g and ß-gal
release). Wells with DHD-K12 target cells or PBMC cul-
tured alone were considered as controls and the corre-
sponding spots were subtracted from the number of
spots obtained in the co-cultures.
Statistical analysis
The results were analyzed by non parametric Mann
Whitney t test, using GraphPad Prism version 5.00 for




Transfected tumour cells DHD-K12 showing b-gal
expression ranged between 50% and 60% in different
experiments (Figure 1). No background staining was
observed in cells transfected with Lipofectamine 2000
without DNA, performed as negative control (not
shown).
IFN-g release
The specific T-cell recognition of the CSH-275 peptide
antigen was evaluated in vitro through the analysis of
the IFN-g release. The stimulation of PBMC from DHD-
K12-inoculated rats, using different concentration of
CSH-275 peptide, induced the production of IFN-g in a
dose-dependent manner. The response induced by con-
centrations of 4-10 μg/ml of the peptide antigen was
even higher than that induced by the mitogen. PBMC
from control rat did not respond to the CSH-275 pep-
tide, while they had an IFN-g response to mitogen simi-
lar to that observed in DHD-K12-inoculated rats. These
findings confirmed that DHD-K12-inoculated rats
develop a specific immune response against the CSH-
275 peptide expressed on DHD-K12 cells [16], and that
such response is measurable in vitro by the ELISpot
assay for IFN-g. In Figure 2 are reported the mean sti-
mulation indexes obtained in three different
experiments.
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Cytotoxic activity
DHD-K12-inoculated rats developed aspecific cytolytic T
cell response towards tumor cells. In Figure 3A are
depicted the histograms representing the number of
spots corresponding to the release of b-gal from lysed
target cells. In these experimental settings, 2 × 105/well
PBMC were plated in the presence of different number
of DHD-K12 b-gal transfected target cells. Only PBMC
from DHD-K12 inoculated rats developed a cytotoxic
activity against the tumour, while control rats were
unable to recognize and kill target cells. The number of
induced spots was dose-dependent and increased in the
presence of higher number of target cells up to 2 × 104.
Peak concentration corresponded to 2 × 104 target cells.
Higher concentrations did not lead to a significant
increase in spots (P = 0.14).
To further demonstrate the in vitro specific cytotoxi-
city of PBMC from intact or DHD-K12-inoculated rats
against DHD-K12 cell line we utilized a colorimetric
assay (CytoTox 96 kit Promega) that quantitatively mea-
sures the release of lactate dehydrogenase (LDH) from
killed tumor cells. In Figure 3B the results, expressed as
percent of specific lysis confirm, at comparable effector:
target ratio used in Lysispot, the specific cytotoxic activ-
ity against DHD-K12 tumor cell line.
Cytotoxicity and IFN-g secretion evaluated by the dual-
colour LysiSpot assay
The dual-colour assay allowed to determine both the
induction of cytotoxic effects in association with the
production of IFN-g in response to the specific recogni-
tion of the tumor cells.
DHD-K12 b-gal transfected cells (2 × 104) were cul-
tured with 2 × 105 PBMC from control or tumor har-
bouring rats. Trough the combined analysis of the spots
of different colours, a differential counts of the number
of lysed cells (pure red spots), the number of PBMC
secreting IFN-g (pure blue spots) and the number of
cells that simultaneously secreted IFN-g and lysed the
targets (violet spots combining both colours) was
allowed. The histograms depicted in Figure 4, represent
the results of three different experiments and show that
IFN-g secretion and cytotoxicity are distinct CTLs func-
tions that can be independently regulated. Therefore, in
our experimental conditions, 55% of the overall immune
Figure 2 IFN-g release. IFN-g-ELISpot results from three different
experiments, expressed as number of spots per well (mean ± SD),
showed the immune-response of DHD-K12-inoculated rats (dark
grey) against CSH-275 peptide. No effect was produced on PBMC
from control rats (light grey). Increasing concentration of peptide
yielded an increasing numbers of IFN-g producing PBMC. Under
each histogram there is the corresponding image illustrative of blue
spots. As negative contros we showed the non stimulated PBMC
(W/O).
Figure 3 Panel A - LysiSpot assay . LysiSpot assay results,
expressed as net number of spots per well (spots from wells
containing only target cells were subtracted), from four different
experiments (mean ± SD). Increasing numbers of target cells were
plated in short term cultures with effector cells (2 × 105/well PBMC).
Spots were the imprint of b-gal, released by the transfected DHD-
K12 target cells after lysis. Cytotoxic activity of PBMC from DHD-K12-
inoculated rats or control rats are represented by dark and light
grey respectively. Panel B - LDH-Cytotoxicity assay. Cytotoxic activity
expressed as percent of specific lysis (mean ± SD) of DHD-K12
target cells from PBMC of intact (control) or DHD-K12-inoculated
rats (Primed) evaluated by Promega CytoTox 96 kit. Concentration
ratio of effector and target cells was 10:1 (light grey), 5:1 (dark grey),
2.5:1 (white), 1.25:1 (black) and corresponding respectively to 2 ×
104,1 × 104, 5 × 103, 2.5 × 103 of DHD-K12 target cells.
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activated cells developed a full lytic activity and a large
portion of these cells (65%) also released IFN-g. The
remaining 45% produced IFN-g but were not cytotoxic.
Discussion
The development of sensitive assays to assess specific T
cell responses against cancer represents a key tool for
both experimental and clinical immunology as well as in
the pre-clinical and clinical settings [9,22,23].
In recent years, the increase in the understanding the
biology of tumor cells and the identification of tumor
antigens capable to elicit potent and effective T cell
immune responses, opened an avenue of possibilities for
the design of specific vaccination strategies based on the
use of peptide antigens [24,25]. Is therefore of utmost
relevance the development of assays that can provide
qualitative and quantitative measurement of the anti-
tumour immune responses.
Several techniques for immune monitoring of specific
T-cell responses are now available including assays
which provide information about the specific T cell
recognition of cancer antigens, irrespective of their func-
tional activity, such as those based on the use of tetra-
mers [26], assays aimed at detecting T-cell precursors
by amplifying cells that proliferate in response to the
antigenic stimulation [27], as well as assays that measure
the secretion of a particular cytokine [28] All these test
do not provide information about the anti-tumour lytic
activity of the immune cells [9,28]. On the other hand,
the assessment of cytotoxicity, is generally measured on
the basis of the Chromium or Europium release assay,
Such cytotoxicity assays measure the percentage of tar-
gets lysed by a bulk population of effectors, but they do
not provide any information about the frequency of cyo-
toxic T cells.
The biologic relevance of these methods is therefore
limited to the specific information about cytokine secre-
tion, extent of cell-mediated cytotoxicity and/or prolif-
eration in response to tumour antigens. Nevertheless,
antigen-activated T cells do not necessarily secrete the
same set of cytokines, neither cytotoxicity always corre-
lates with cytokine secretion in a bulk T cell population
[12,14,29].
It is well recognised that activated CD8+ T cells med-
iate their functions by secretion of different cytokines,
including IFN-g, that initiate a “lytic program” ending
with a direct perforin-mediated transfer of lytic enzymes
(granzyme) capable of inducing apoptosis in target cells
[10,30-32].
As previously demonstrated in vitro by Snyder JE et al.
[15] the cytotoxic activity and IFN-g production by
CTLs are independent functions which may follow dif-
ferent regulatory pathways. In fact, not all CD8+ T cells
function as “killer” cells. Indeed, during the acute phase
of a CD8+ T-cell response, IFN-g production, cytotoxi-
city, and proliferation appeared as independently regu-
lated in cancer and infections [15,33,34].
The simultaneous determination of the different func-
tions exerted by T cells can offer a valuable tool for ex
vivo analysis of the immune response against cancer as
well as infections, but also in assessing autoimmune dis-
eases as well as to identify correlates of immune protec-
tion exploitable for therapeutic strategies based on
vaccine development.
The assay we developed is based on a dual-colour Lysi-
Spot method aimed at measuring the extent of the recog-
nition of tumour cells by CTLs, as elicited in a rat model
harbouring a colorectal tumour induced by the DHD-
K12 cell line. In this assay the simultaneous determina-
tion of the different functions exerted by T cells can offer
a valuable tool for ex vivo analysis of the immune
response against cancer as well as furnish a base to evalu-
ate the number and function of lytic effector cell.
DHD-K12 cells naturally express a tumour-associated
antigen that induces specific cytotoxic responses in
immune competent syngeneic animals [16,17]. The syn-
thetic nonapeptide antigen, CSH-275, was previously
used in a vaccination protocol and gave proof of the
induction of an antitumour activity as elicited by the
vaccination [17]. By the ELISPOT assay illustrated in
Figure 1 we have further demonstrated the specific
recognition of this nonapeptide, epitope constitutionally
express in DHD-K12 cells
In the present study, the DHD-K12 cell line was tran-
siently transfected, using a pCMV-LacZ vector
Figure 4 Dual-colour LysiSpot assay. Dual-colour LysiSpot assay
results from three different experiments (mean ± SD), expressed as
net number of spots per well (spots from control wells containing
only target cells or PBMC cultured alone were subtracted from the
spots counted in the cocultures. DHD-K12 transfected cells (2 × 104/
well) were cocultured with 2 × 105/well PBMC. The panel shows the
image of the different spots left on the wells at the end of assay: 1)
pure red spots indicate cell lysis by IFN-g non-producing cells; 2)
pure blue spots indicate IFN-g secreting cells; 3) violet spots indicate
cell lysis by IFN-g producing cells. Dark and light grey bars represent
number of spots from DHD-K12-inoculated rats or from control rats
respectively.
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containing the nuclear-targeted b-gal coding region.
This method permits to easily “mark” [35] the tumour
cell line. We chose to use the plasmid DNA- Lipofecta-
mine complex to introduce a gene expressing a marker
protein because this methodology with non-viral vectors,
either plasmids or siRNAs, efficiently transfects human
colon cancer cells [36-39] as well primary neurons. In
the latter, optimized protocols gives transfection effi-
ciencies of 20-30%, a great improvement compared with
less than 3% previously reported [40].
Non-viral vectors have been receiving increasing
attention, since they are safer and cheaper, and can be
produced easily in large quantities. A recent study com-
paratively examined a panel of non-viral gene transfer
systems in several cells of different origins, including
human colorectal carcinoma, and in human primary
cells [41]. In this work, the authors evaluated the
requirements for successful transfection and the poten-
tial for optimization of transfection efficiency. Their
results indicate that this high efficiency methodology
can be sufficiently optimized to offer a feasible approach
for gene delivery into a wide range of cells, including
human tumor cells [41].
Using a commercially available IFN-g ELISpot assay,
we confirmed an antigen-specific, dose-dependent, IFN-
g release by PBMC isolated from rats when primed with
DHD-K12 cells.
The dual-colour assay was developed by combining an
IFN-g ELISpot assay, a LysiSpot assay, and b-gal trans-
fection of the target cells. This assay allowed us to
detect simultaneously the lysis of tumour target cells
and the identification of CTLs producing IFN-g. The
use of a dual-colour software programme, allowed to
count separately the spots of three different colours,
thus overcoming the reported difficulty in discerning
the difference in the colours of the spots previously
described The LysiSpot was performed with a number
of target cells high enough to virtually allow all CTLs
present in the culture to find the target, however
respecting the limit of an acceptable background level of
positive spots. The assessment of effector/target cells
ratio was determined in preliminary experiments (data
not shown) to ensure that all the key parameters to
assess T cell cytotoxicity were optimized.
The method highlighted that in the present experi-
mental model the tumour antigen-specific immune
response was bound to killing target cells in the propor-
tion of 55%, while 45% of activated cells were not cyto-
toxic but released IFN-g. Those cells could represent an
incomplete stage of differentiation toward fully devel-
oped effector cells [42].
DHD-K12 cells naturally express a tumour-associated
antigen that induces specific cytotoxic responses in
immune competent syngeneic animals [16,17]. The syn-
thetic nonapeptide antigen, CSH-275, was previously
used in a vaccination protocol and gave proof of the
induction of an antitumour activity as elicited by the
vaccination [17]. These data demonstrate that CSH-275
is full recognized by ex vivo lymphocytes from DHD-
K12 primed rats and since CSH-275 is a major epitope
identified on the TLP (Tumour Liberated Proteins) iso-
lated from human lung, colon and breast cancer [18-20]
it is evident the importance of this antigen as a potential
target for new diagnostic and/or therapeutic approaches
to human cancer.
Conclusions
In this study we show a reproducible and easy technique
capable of measuring even low frequencies of antigen-
specific cytolytic cells against tumour, and provided
further evidence of the multiple aspects of the different
regulatory pathways governing the induction of cytolytic
mechanisms.
The proposed lysispot assay, and this rat colon carci-
noma model, could be used to evaluate the specific cell
mediated immunity and or cytochine production in pre-
clinical study, pharmacological treatment and develop-
ment of immune intervention.
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